Autoimmune Hepatitis In Tunisia. Retrospective Multicentric Study About 83 Cases.

##plugins.themes.academic_pro.article.sidebar##

Published Oct 29, 2010
Download
pdf
Vol. 88 No. 11 (2010): Issue Nov 2010

##plugins.themes.academic_pro.article.main##

Radhouane Debbeche
Nadia Maàmouri
Salem Ajmi
Mohamed Moussaddek Azzouz
Nabyl Ben Mami
Mohamed Hedi Dougui
Azza Filali
Abdeljabbar Ghorbel
Faouzi Khedhiri
Mohamed Salah Krichene
Taoufik Najjar
Hammouda SAFFAR
Bechir Zouari

Abstract

Background: Autoimmune hepatitis (AIH) is a chronic inflammatory condition of the liver of unknown etiology. Its epidemiological and anatomoclinical characteristics and its outcome were unknown in Tunisia.
Aim : To analyse epidemiological, anatomoclinical, immunological and histological aspects of AIH and to determine factors predicting relapse after treatment and death of this disease in Tunisia.
Methods Patients presenting with AIH between January 1996 and December 2004 were evaluated in retrospective multicentric study. The diagnosis of AIH was established according to the criteria of the revised score of the international autoimmune hepatitis group (1999)
Results:Eighty three patients were identified (70 female; mean age = 49 +17,9 years). 63% presented probable AIH and 37% presented definite AIH. Thirty two percent presented with the acute pattern. Eighty three per cent of cases were type I AIH and 5 % of cases were type II HAI. Fifty seven percent of the patients were cirrhotic at presentation. Associated autoimmune diseases was seen in 27 patients, dominated by diabetes, autoimmune thyroïditis and SjÖgren’s syndrom. An overlap syndrome was diagnosed in 25% of cases; primary biliary Cirrhosis-AIH in 20% of cases and primary sclérosing cholangitis-AIH in 5% of cases. Fifty patients were treated by glucocorticoids as monotherapy or in combination with azathioprine. Complete rémission was achieved in 90% of cases. Fourteen percent relapsed within a median time of 12 months. Factors associated with relapse were: treatment with Azathioprine <18 months, absence of lobular necrosis and anti-nuclear antibody (+) profile. Mortality was observed in 17 % of cases. Factors associated with death were encephalopathy as an independant factor and treatment with Azathioprine < 18 months.
Conclusion: In Tunisia, epidemiological and clinical characteristics of AIH were similar to those reported in the literature but with a higher frequency of cirrhosis at presentation. Treatment with Azathioprine < 18 months was the main factor associated with relapse and represented with encephalopathy a factor associated with
death.

Keywords:

Autoimmune hepatitis, Overlap syndrome,

##plugins.themes.academic_pro.article.details##

References

  1. Johson PJ, McFarlane IG. Meeting report: international autoimmune hepatitis group. Hepatology 1993 ; 18 : 998-1005.
  2. Alvarez F, Berg PA, Bianchi FB et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999 ; 31 : 929-38.
  3. Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002 ; 36 : 479-97.
  4. Hegarty JE, Nouri-Aria KT, Portmann B et al. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology 1983 ; 3 : 685-9.
  5. Czaja AJ, Ludwig J, Baggenstoss AH et al. Corticosteroid-treated chronic active hepatitis in remission. Uncertain prognosis of chronic persistent hepatitis. N Engl J Med 1981; 304 : 5-9.
  6. Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 2006 ; 43 : 532-8.
  7. Verslype C, George C, Buchel E, Nevens F, Van Steenbergen W, Fevery J. Diagnosis and treatment of autoimmune hepatitis at age 65 and older. Aliment Pharmacol Ther 2005 ; 21 : 695-9.
  8. Ferrari R, Pappas G, Agostinelli D et al. Type 1 autoimmune hepatitis : patterns of clinical presentation and differential diagnosis of the acute type.. QJM 2004 ; 97 : 407-12.
  9. Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A. Factors predicting relapse and poor outcome in type 1 autoimmune hepatitis : role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 2004 ; 99 : 1510-6.
  10. Czaja AJ, Donaldson PT. Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis. Am J Gastroenterol 2002 ; 97 : 2051-7.
  11. Choudhuri G, Somani KS, Baba CS, Alexander G. Autoimmune hepatitis in India: profile of uncommon disease. BMC Gastroenterol 2005 ; 15 : 27.
  12. Hakem D, Berrah A, Berkane S et al. Autoimmune chronic active hepatitis :Anatomoclinic's study of 50 patients. Rev Med interne 2005 ; 26 : 858-65.
  13. Miyake Y, Iwasaki Y, Sakaguchi K, Shiratori Y. Clinical features of Japanese male patients with type 1 autoimmune hepatitis. Aliment Pharmacol Ther 2006 ; 24 : 519-23.
  14. Granito A, Muratori L, Pappas G et al. Clinical features of type 1 autoimmune hepatitis in elderly Italian patients. Aliment Pharmacol Ther 2005 ; 21 : 1273-9.
  15. Hurlburt KJ, McMahon, Deubner H, Hsu-Trawinski, Williams JL, Kowdley JV. Prevalence of autoimmune liver disease in Alaska natives. Am J Gastroenterol 2002 ; 97 : 2402-7.
  16. Yamamoto K, Terada R, Okamoto R et al. A scoring system for primary biliary cirrhosis and its applications for variant forms of autoimmune liver disease. J Gastroenterol 2003 ; 38 :52-9.
  17. Chazouillères O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998 ; 28 : 296-301.
  18. Czaja AJ, Menon KV, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 2002 ; 35 :890-7.
  19. Donaldson PT, Doherty DG, Hayllar KM, McFarlane IG, Johnson PJ, Williams R. Susceptibility to autoimmune chronic active hepatitis: human leucocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 1991 ; 13 : 701-6.
  20. Czaja AJ, Davis GL, Ludwig J, Taswell HF. Complete resolution of inflammatory activity following corticosteroid treatment of HBs Ag negative chronic hepatitis. Hepatology 1984 ; 4 : 622-7.
  21. Kanzler S, Gerken G, Lohr H et al. Duration of immunosuppressive therapy in autoimmune hepatitis. J Hepatol 2001 ; 34 : 354-5.
  22. Hino T, Kumashiro R, Ide T et al. Predictive factors for remission and death in 73 patients with autoimmune hepatitis in Japan. Int J Mol Med 2003 ; 11 : 749-55.